Nitric oxide synthase inhibitor treatment for septic shock antimigraine

Drugs of the Future

Volumn 23, Issue 2, 1998, Pages 123-132

  Prous, J R ^a   Wroblewski, T ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; ANTIMIGRAINE AGENT; AUTACOID; CANAVANINE; CITRULLINE; CYTOKINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; GUANIDINE DERIVATIVE; ICOSANOID; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE INHIBITOR; ORNITHINE; OXYGEN RADICAL;

AREA UNDER THE CURVE; CITRIC ACID CYCLE; CLINICAL TRIAL; DRUG DISPOSITION; DRUG EFFICACY; DRUG INDICATION; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MEDIATOR RELEASE; MIGRAINE; NONHUMAN; REVIEW; SEPTIC SHOCK; SUBCUTANEOUS DRUG ADMINISTRATION; UREA CYCLE;

EID: 0031918240     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1998.023.02.445975     Document Type: Review

References (84)

1. G-methyl-D-arginine. Synth Commun 1994, 24: 2789-92.
2. G-mono-, di-and trimethylated arginines. Acta Biochim Biophys Acad Sci Hung 1977, 12: 191-6.
3. G-Monomethyl-L-arginine hydrochloride derivs. and their use in the treatment of septic shock. EP 651741, JP 95509239, WO 9402453.
4. G-methylarginine. Anal Biochem 1974, 57: 310-2.
5. G-monoalkyl-L-arginine and related cpds. WO 9426701.
6. G-monomethyl-L-arginine hydrochloride. WO 9730972.
7. Pundak, S., Wilchek, M. Synthesis of guanidino-N-alkylarginines by the use of polymeric pseudoureas. J Org Chem 1981, 46: 808-9.
8. G-methyl-(L-)-arginine and its analytical characterization. Synth Commun 1991, 21: 99-105.
9. Young, L.S., Martin, W.J., Meyer, R.D., Weinstein, R.J., Anderson, E.T. Gram-negative rod bacteremia: Microbiologic, immunologic, and therapeutic considerations. Ann Intern Med 1977, 86: 456-71.
10. Perlino, C.A., Rimland, D. Alcoholism, leukopenia and pneumococcal sepsis. Amer Rev Respir Dis 1985, 132: 757-60.
11. Bone, R.C., Balk, R.A., Cerra, F.B., Dellinger, R.P., Fein, A.M., Knaus, W.A., Schein, R.M., Sibbald, W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. ACCP/SCCM Consensus Conference Committee. Chest 1992, 101: 1644-55.
12. Nyström, P.-O. The systemic inflammatory response syndrome: Definitions of aetiology. J Antimicrob Chemother 1998, 41(Suppl. A): 1-7.
13. Sibbald, W.J., Doig, G., Inman, K.J. Sepsis, SIRS and infection. Intensive Care Med 1995, 21: 299-301.
14. Moncada, S., Palmer, R.M.J., Higgs, E.A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43: 109-42.
15. Kerwin, J.F. Jr., Heller, M. The arginine-nitric oxide pathway: A target for new drugs. Med Res Rev 1994, 14: 23-74.
16. Griffith, O.W., Stuehr, D.J. Nitric oxide synthases: Properties and catalytic mechanism. Annu Rev Physiol 1995, 57: 707-36.
17. Marietta, M.A. Nitric oxide synthase structure and mechanism. J Biol Chem 1993, 268: 12231-4.
18. Palmer, R.M.J., Bridge, L., Foxwell, N.A., Moncada, S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Brit J Pharmacol 1992, 105: 11-2.
19. O'Connor, K.J., Moncada, S. Glucocorticoids inhibit the induction of nitric oxide synthase and the related cell damage in adenocarcinoma cells. Biochim Biophys Acta 1991, 1097: 227-31.
20. Boughton-Smith, N.K., Evans, S.M., Laszlo, F., Whittle, B.J.R., Moncada, S. The induction of nitric oxide synthase and intestinal vascular permeability by endotoxin in the rat. Brit J Pharmacol 1993, 110: 1189-95.
21. Boughton-Smith, N.K., Evans, S.M., Hawkey, C.J., Cole, A.T., Balsitis, M., Whittle, B.J.R., Moncada, S. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993, 342: 338-40.
22. Middleton, S.J., Shorthouse, M., Hunter, J.O. Increased nitric oxide synthesis in ulcerative colitis. Lancet 1993, 341: 465-6.
23. Miller, M.J., Zhang, X.-J., Sadowska-Krowicka, H., Chotinaruemol, S., McIntyre, J.A., Clark, D.A., Bustamante, S.A. Nitric oxide release in response to gut injury. Scand J Gastroenterol 1993, 28: 149-54.
24. Miller, M.J., Sadowska-Krowicka, S., Chotinaruemol, S., Kakkis, J.L., Clark, D.A. Amelioration of chronic ileitis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 1993, 264: 11-6.
25. G-nitro-L-arginine, and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 1994, 199: 147-54.
26. Nava, E., Palmer, R.M.J., Moncada, S. Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 1991, 338: 1555-7.
27. Wright, C.E., Rees, D.D., Moncada, S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992, 26: 48-57.
28. Parratt, J.R. Nitric oxide in sepsis and endotoxaemia. J Antimicrob Chemother 1998, 41(Suppl. A): 31-9.
29. Wu, C.C., Chen, S.J., Szabó, C., Thiemermann, C., Vane, J.R. Inhibition of nitric oxide formation with aminoguanidine attenuates the delayed circulatory failure in endotoxic shock in the rat. Brit J Pharmacol 1994, 112(Suppl.): Abst 221P.
30. Cai, M., Sakamoto, A., Ogawa, R. Inhibition of nitric oxide formation with L-canavanine attenuates endotoxin-induced vascular hyporeactivity in the rat. Eur J Pharmacol 1996, 295: 215-20.
31. Fatehi-Hassanabad, Z., Burns, H., Augley, E.A., Paul, A., Plevin, R., Parrat, J.R., Furman, B.L. Effects of L-canavanine, an inhibitor of inducible nitric oxide synthase, on endotoxin mediated shock in rats. Shock 1996, 6: 194-200.
32. Griffiths, M.J.D., Messent, M., MacAllister, R.J., Evans, T.W. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Brit J Pharmacol 1993, 110: 963-8.
33. Misko, T.P., Moore, W.M., Kasten, T.P., Nickols, G.A., Corbett, J.A., Tilton, R.G., McDaniel, M.L, Williamson, J.R., Currie, M.G. Selective inhibition of the inducible nitric oxide synthase by aminoguanidine. Eur J Pharmacol 1993, 233: 119-25.
34. ω-nitro-L-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur J Pharmacol 1996, 300: 99-104.
35. Southan, G.J., Szabó, C., Thiemermann, C. Isothioureas: Potent inhibitors of nitric oxide synthases with variable isoform selectivity. Brit J Pharmacol 1995, 114: 510-6.
36. Thiemermann, C., Ruetten, H., Wu, C.-C., Vane, J.R. The multiple organ dysfunction syndrome caused by endotoxin in the rat: Attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Brit J Pharmacol 1995, 116: 2845-51.
37. Hasan, K., Heesen, B.-J., Corbett, J.A., McDaniel, M.L., Chang, K., Allison, W., Wolffenbuttel, B.H.R., Williamson, J.R., Tilton, R.G. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 1993, 249: 101-6.
38. Ruetten, H., Southan, G.J., Abate, A., Thiemermann, C. Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Brit J Pharmacol 1996, 118: 261-70.
39. Laszlo, F., Evans, S.M., Whittle, B.J.R. Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur J Pharmacol 1995, 272: 169-75.
40. Laszlo, F., Whittle, B.J.R., Moncada, S. Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Brit J Pharmacol 1994, 111: 1309-15.
41. Schlag, G., Redl, H., Gasser, H., Davies, J., Rees, D., Grover, R. Delayed treatment with the NO-synthase inhibitor 546C88 in a baboon model of septic shock. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A263.
42. G-monomethyl-L-arginine. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst G-56.
43. G-methylarginine hydrochloride) in rat and dog. Xenobiotica 1997, 27: 1259-71.
44. G-monomethylarginine (546C88) in human plasma by pre-column o-phthalaldehyde derivatisation and high-performance liquid chromatography. J Chromatogr B 1997, 696: 117-22.
45. Petros, A., Bennett, D., Vallance, P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991, 338: 1557-8.
46. Petros, A., Lamb, G., Leone, A., Moncada, S., Bennett, D., Vallance, P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994, 28: 34-9.
47. Andersson, J., Watson, D., Donaldson, J., Grossman, S., Smithies, M., Le Gall, J.-R. Multicentre, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: Effect in patients with confirmed bacterial infection. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst G-48b.
48. Watson, D., Beerahee, M., Holzapfel, L., Lodato, R., Grover, R., Andersson, J. Multicentre, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: Effect on plasma nitrate profile. 37th Intersci Conf Antimicrob Agents Chemother (Sept 28-Oct 1, Toronto) 1997, Abst G-40.
49. Anzueto, A., McLuckie, A., Holzapfel, L., Grove, G., Mottola, D., Takala, J. Multicentre, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: Safety profile. Chest 1997, 112(3): 88S.
50. Anzueto, A., Lodato, R., Lorente, J., Holzapfel, L., Grover, R., Takala, J. Multicenter placebo-controlled, double-blind trial of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: Acute hemodynamic effects Amer J Respir Crit Care Med 1997, 155(4, Part 2): A263.
51. Bakker, J., Lodato, B., Donaldson, J., Grover, R., Guntupalli, K., Takala, J. Multicenter, placebo-controlled double-blind trial of the nitric oxide synthase inhibitor 546C88 in patients with septic shock: Acute effects on the pulmonary circulation. Amer J Respir Crit Care Med 1997, 155(4, Part 2): A702.
52. Lassen, L.H., Ashina, M., Christiansen, I., Ulrich, V., Olesen, J. Nitric oxide synthase inhibition in migraine. Lancet 1997, 349: 401-2.
53. Lassen, L.H., Ashina, M., Christiansen, I., Ulrich, V., Grover, R., Donaldson, J., Olesen, J. Nitric oxide synthase inhibition: A new principle in the treatment of migraine attacks. Cephalalgia 1997, 17(3): 423.
54. White, R.P., Deane, C., Vallance, P., Markus, H.S. Nitric oxide synthase inhibition in humans reduces cerebral blood flow but not the hyperemic response to hypercapnia. Stroke 1998, 29: 467-72.
55. 546C88 development status. Glaxo Wellcome Company Communication 1997, December 1.
56. Peterson, D.A., Peterson, D.C., Archer, S., Weir, E.K. The non specificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun 1992, 187: 797-801.
57. Thomas, G., Myers, A., Farhat, M., Cathapermal, S., Ramwell, P.W. Effect of N-substituted arginine compounds on blood pressure in anesthetized rats. J Pharmacol Exp Ther 1992, 261: 875-8.
58. Oyanagui, Y., Sato, S. Superoxide dismutases and anti-oxidants protected mice from no-reflow and necrotic damage induced by ischemia. Free Radic Res Commun 1993, 18: 147-57.
59. Cappendijk, S.L.T., de Vries, R., Dzoljic, M.R. Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine-dependent mice. Neurosci Lett 1993, 162: 97-100.
60. Stefanovic-Racic, M., Myers, K., Meschter, C., Coffey, J.W., Hoffman, R., Evans, C.H. N-Monomethylarginine, an inhibitor of nitric oxide synthase, suppresses the onset of adjuvant arthritis in rats. 55th Annu Meet Amer Coll Rheumatol (Nov 7-11, San Antonio) 1993, Abst 36.
61. Evans, C.H., Coffey, J.W., Hoffman, R., Meschter, C., Meyers, K., Stefanovic-Racic, M. N-Monomethylarginine, an inhibitor of nitric oxide synthase suppresses the onset of adjuvant arthritis in rats. IAIS World Cong Inflamm (Oct 10-15, Vienna) 1993, Abst 149.
62. Alak, A.M., Moy, S. Determination of N-monomethyl-L-arginine in biological samples by high performance liquid chromatograph. Pharm Res 1993, 10(10, Suppl.): Abst APQ 1120.
63. Rongen, G.A., Smits, P., Thien, T. L-NMMA attenuates the forearm vasodilator response to acetylcholine but not to adenosine-5′-triphosphate in man. Pharm World Sci 1994, 16: D7.
64. G-monomethyl-L-arginine in the isolated intracranial artery of dog. Jpn J Pharmacol 1994, 64(Suppl. 1): Abst O-94.
65. G-monomethyl-L-arginine (L-NMMA) on morphological changes induced by bacterial lipopolysaccharides (LPS) and tumor necrosis factor α (TNFα) on rat tracheal epithelial cells in culture. Naunyn-Schmied Arch Pharmacol 1994, 350(Suppl.): Abst 14.
66. Akarid, K., Levacher, M., Sinet, M., Chau, F., Desforges, B., Pocidalo, M.A. Effect of in vivo administration of NO synthase inhibitor on immune abnormalities observed in murine AIDS. 34th Intersci Conf Antimicrob Agents Chemother (Oct 4-7, Orlando) 1994, Abst 1106.
67. G-monomethyl-L-arginine in a marginal renal subcapsular mouse islet transplant model. 15th World Cong Transplant Soc (Aug 28-Sept 2, Kyoto) 1994, Abst 392.
68. Khraibi, A., Bracamonte, M. Role of prostaglandins in the natriuresis of L-NMMA infusion in SHR and WKY rats. FASEB J 1994, 8(5, Part 2): Abst 4840.
69. Hansen, P.R., Haunso, S. Effects of nitric oxide synthase inhibition on myocardial capillary permeability and reactive hyperaemic response. Eur Heart J 1994, 15(Suppl.): Abst 1846.
70. Oddis, C.V., Hattler, B.G., Moorer, G., Simmons, R.L., Finkel, M.S. The nitric oxide inhibitor, L-NMMA, alters E-C coupling in the heart. J Amer Coll Cardiol 1994, Suppl.: Abst 917-67.
71. G-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm. Brit J Clin Pharmacol 1994, 38: 311-5.
72. G-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm. Brit J Clin Pharmacol 1994, 38: 307-10.
73. Uchida, Y., Tsukahara, F., Irie, K., Nomoto, T., Muraki, T. Possible involvement of L-arginine-nitric oxide pathway in modulating regional blood flow to brown adipose tissue of rats. Naunyn-Schmied Arch Pharmacol 1994, 349: 188-93.
74. ω-monomethyl-L-arginine on short-term RR interval and systolic blood pressure oscillations. J Cardiovasc Pharmacol 1994, 24: 323-7.
75. G-monomethyl L-arginine (NMMA) prevents inflammatory renal disease and enhances renal blood flow. Clin Res 1994, 42(2): 139A.
76. G-monomethylarginine, reduces carrageenan-induced pleurisy in the rat. J Pharmacol Exp Ther 1995, 273: 1295-9.
77. G-monomethyl-L-arginine on microvascular blood flow in healthy volunteers. Brit J Clin Pharmacol 1995, 39: 92P.
78. Schedin, U., Albert, J., Hjemdahl, P., Lindqvist, M., Melcher, A., Frostell, C. Infusion of L-NMMA reduces human nasal nitric oxide levels. Brit J Anaesth 1996, 76(Suppl. 2): Abst A.365.
79. G-monomethyl-L-arginine, an inhibitor of nitric oxide production. Proc Amer Assoc Cancer Res 1994, 35: Abst 1500.
80. G-monomethyl-L-arginine (L-NMMA) on hemostatic system activation in vivo in man. Thromb Haemost 1995, 73(6): Abst 67.
81. Nishida, K., Chung, D.C., Kikuchi, Y., Booke, M., Traber, L.D., Traber, D.L. Effects of nitric oxide synthase inhibitor on left ventricular end-systolic pressure-diameter relationship in healthy sheep. FASEB J 1995, 9(3, Part 1): Abst 3231.
82. Patch, D., McCormick, P.A., Greenslade, L., Dick, R., Burroughs, A.K. The effect of a nitric oxide synthase inhibitor on system haemodynamics in cirrhotic patients. Gastroenterology 1995, 108(4, Suppl.): A1144.
83. Tousoulis, D., Tentolouris, C., Crake, T., Gialafos, J., Davies, G., Toutouzas, P. Inhibition of nitric oxide synthesis in coronary arteries. Int Angiol 1995, 14(1, Suppl. 1): Abst 3.01.
84. Albert, J., Frostell, C., Schedin, U., Lindqvist, M., Melcher, A., Hjemdahl, P. Infusion during 60 min of L-NMMA to healthy volunteers. Brit J Anaesth 1996, 76(Suppl. 2): Abst A.274.